Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06915753 · ClinicalTrials.gov registry record · Phase 1

Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations

A Phase 1 study of Advanced Solid Tumors and Solid Tumors, sponsored by Tyra Biosciences.

Recruiting
Registry status
Phase 1
Development phase
100
Enrollment target
16
Study locations

NCT06915753 is a Phase 1 study of Advanced Solid Tumors and Solid Tumors that is actively recruiting participants, run by Tyra Biosciences. The registered enrollment target is 100 participants, below the 198-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (49% lower). The trial reports 16 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06915753, a Phase 1 study of Advanced Solid Tumors and Solid Tumors, is actively recruiting participants, sponsored by Tyra Biosciences.

RECRUITING
Registry status
Phase 1
Development phase
100 participants
Enrollment target
16
Study locations

Study Summary

A Phase 1 study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamic (PD), and preliminary antitumor activity of TYRA-430 in cancers with FGF/FGFR pathway aberrations, including locally advanced/metastatic hepatocellular carcinoma and other advanced solid tumors.

Conditions Studied

Advanced Solid Tumors Solid Tumors Solid Tumor, Adult Metastatic Hepatocellular Carcinoma FGFR3 Gene Mutation FGFR3 Gene Alteration FGFR Gene Amplification FGFR Gene Alterations FGFR4 Gene Mutation FGFR4 Gene Fusions

Interventions

  • DRUG TYRA-430

Study Locations (16)

Other

  • Asan Medical Center - Seoul
  • Samsung Medical Center - Seoul
  • Seoul National University Hospital - Seoul
  • Severance Hospital, Yonsei University Health System - Seoul
  • National Taiwan University Hospital - Taipei
  • Taipei Veterans General Hospital - Taipei

California

  • USC Norris Comprehensive Cancer Center - Los Angeles
  • UCSF Medical Center at Mount Zion - San Francisco
  • Stanford Cancer Institute - Stanford

Kansas

  • The University of Kansas Medical Center - Westwood

Maryland

  • John Hopkins University - Baltimore

Massachusetts

  • Mass General Cancer Center - Boston

Michigan

  • Karmanos Cancer Institute - Detroit

New York

  • Columbia University Irving Medical Center - New York

Tennessee

  • Sarah Cannon Research Institute Oncology Partners - Nashville

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2025-04-24
Est. Completion 2028-09
Phase Phase 1

Sponsor

Tyra Biosciences

6 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06915753

The ClinicalTrials.gov registry entry for NCT06915753 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 198-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (49% lower). The listed sponsor is Tyra Biosciences, which has 6 total studies on file at ClinicalTrials.gov.

The record links to 10 conditions, with Advanced Solid Tumors appearing as the primary indexed condition, and to 1 intervention - of which TYRA-430 is the first listed.

NCT06915753 reports 16 study locations spanning 9 distinct geographic areas - top geographies include Other, California, Kansas.

Frequently Asked Questions

What is clinical trial NCT06915753 about?

NCT06915753 is a clinical study titled "Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations". A Phase 1 study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamic (PD), and preliminary antitumor activity of TYRA-430 in cancers with FGF/FGFR pathway aberrations, including locally advanced/metastatic hepatocellular carcinoma and other advanced solid tumors.

What is the current status of trial NCT06915753?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 100 participants. The study started on 2025-04-24. Estimated completion is 2028-09.

What conditions does trial NCT06915753 study?

This clinical trial studies the following conditions: Advanced Solid Tumors, Solid Tumors, Solid Tumor, Adult, Metastatic Hepatocellular Carcinoma, FGFR3 Gene Mutation.

What interventions are being tested in trial NCT06915753?

The interventions under investigation include: TYRA-430 (DRUG).

Who is sponsoring clinical trial NCT06915753?

This trial is sponsored by Tyra Biosciences, which has 6 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06915753 being conducted?

This trial has 16 study locations across California, Kansas, Maryland, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Solid Tumors

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Advanced Solid Tumors

All registered trials for this condition

Solid Tumors

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.